Open an account

Sienna Biopharmaceuticals

SNNAQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket open · · Delayed 15 min
No price history for this range.

About SNNAQ

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of aesthetics and medical dermatology. The company is headquartered in Westlake Village, California and currently employs 13 full-time employees. The company went IPO on 2017-07-27. The firm is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The firm's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.

Employees
13
Headquarters
Westlake Village, California
Listed
Jul 27, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
siennabio.com

SNNAQ key statistics

Market cap
31
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
11.73K
Volume
100
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0002
52 Week low
$0.00

Sienna Biopharmaceuticals (SNNAQ) at a glance

Sienna Biopharmaceuticals (SNNAQ) last traded at $0.00, with a market cap of 31 and a price-to-earnings ratio of 0.00.

Volume so far is 100 shares, below the average of 11.73K shares a day.

Over the past year Sienna Biopharmaceuticals has ranged from $0.00 to $0.0002, and now sits 0% of the way up that range.

Sienna Biopharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY19 it reported -$0.27 per share against an estimate of -$0.412.

SNNAQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 33.0% on average.

  1. Q3 FY17: reported -$1.12 per share against an estimate of -$0.7107
  2. Q4 FY17: reported -$0.56 per share against an estimate of -$0.8189
  3. Q1 FY18: reported -$0.85 per share against an estimate of -$0.7347
  4. Q2 FY18: reported -$1.00 per share against an estimate of -$0.8137
  5. Q3 FY18: reported -$0.82 per share against an estimate of -$0.8137
  6. Q4 FY18: reported -$0.93 per share against an estimate of -$0.8549
  7. Q1 FY19: reported -$0.63 per share against an estimate of -$0.515
  8. Q2 FY19: reported -$0.27 per share against an estimate of -$0.412

Similar companies

Companies in the same industry as Sienna Biopharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.